ATP-containing immunoliposomes specific for cardiac myosin

Area of Science:

• Biotechnology and Biomedical Engineering
• Cardiovascular Research
• Drug Delivery Systems

Background:

• Adenosine triphosphate (ATP)-loaded liposomes show efficacy in mitigating ischemic damage across various tissues.
• Targeted delivery of therapeutic agents is crucial for treating localized tissue injury, particularly in the myocardium.

Purpose of the Study:

• To engineer ATP-containing immunoliposomes that specifically recognize and target myosin, a component exposed in ischemic cardiac tissue.
• To evaluate the stability, targeting capability, and functional activity of these novel immunoliposomes for potential in vivo applications.

Main Methods:

• Preparation of ATP-loaded PEGylated liposomes using a freezing-thawing method.
• Conjugation of monoclonal anti-cardiac myosin 2G4 antibody to the liposome surface to create immunoliposomes.
• Characterization of liposome size, size distribution, and ATP release upon antibody attachment.
• Assessment of antibody-specific activity and immunoliposome binding to cardiac myosin using ELISA.

Main Results:

• ATP-containing immunoliposomes specific for cardiac myosin were successfully prepared.
• Antibody attachment did not significantly affect liposome size or cause premature ATP release.
• The anti-myosin antibody retained its specific binding activity, enabling efficient targeting of myosin in vitro.

Conclusions:

• Myosin-specific ATP-loaded immunoliposomes represent a significant advancement in targeted drug delivery for ischemic conditions.
• These immunoliposomes hold promise for providing localized energy support to ischemic myocardium, potentially improving therapeutic outcomes in vivo.